vTv Therapeutics Screens First Patient In CATT1 Pivotal Trial Evaluating Cadisegliatin For Type 1 Diabetes

-2.11%

vTv Therapeutics, Inc. Class A

VTVT

33.90

-2.11%

Cadisegliatin is a potential first-in-class oral liver selective glucokinase activator for T1D, which has been granted Breakthrough Therapy designation by the FDA for T1D

Cadisegliatin has been dosed in over 500 subjects to date, including 300 patients with diabetes

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.